{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:46:47Z","timestamp":1792072007882,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-62479-2","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:46:26Z","timestamp":1784119586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-sensitivity vitreous proteomic analyses reveal involvement of IL-10\/JAK\u2013STAT signaling in the proliferative changes of retinopathy of prematurity"],"prefix":"10.1038","volume":"16","author":[{"given":"Fukutaro","family":"Mano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Shimmyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kuniyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"62479_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","volume":"74","author":"H Blencowe","year":"2013","unstructured":"Blencowe, H., Lawn, J. E., Vazquez, T., Fielder, A. & Gilbert, C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr. Res. 74, 35\u201349 (2013).","journal-title":"Pediatr. Res."},{"key":"62479_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ghir.2004.03.030","volume":"14","author":"LE Smith","year":"2004","unstructured":"Smith, L. E. Pathogenesis of retinopathy of prematurity. Growth Horm. IGF Res. 14, 140\u2013144 (2004).","journal-title":"Growth Horm. IGF Res."},{"key":"62479_CR3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1167\/iovs.07-1356","volume":"49","author":"Y Saito","year":"2008","unstructured":"Saito, Y., Uppal, A., Byfield, G., Budd, S. & Hartnett, M. E. Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Invest. Ophthalmol. Vis. Sci. 49, 1591\u20131598 (2008).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"62479_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A., Kennedy, K. A., Chuang, A. Z. & BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3\u2009+\u2009retinopathy of prematurity. N. Engl. J. Med. 364, 603\u2013615 (2011).","journal-title":"N Engl. J. Med."},{"key":"62479_CR5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl, A. et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394, 1551\u20131559 (2019).","journal-title":"Lancet"},{"key":"62479_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jama.2022.10564","volume":"328","author":"A Stahl","year":"2022","unstructured":"Stahl, A. et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA 328, 348\u2013359 (2022).","journal-title":"JAMA"},{"key":"62479_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","volume":"38","author":"Y Yonekawa","year":"2018","unstructured":"Yonekawa, Y. et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intraretinal bevacizumab or ranibizumab. Retina 38, 1079\u20131083 (2018).","journal-title":"Retina"},{"key":"62479_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.oret.2022.07.005","volume":"7","author":"HT Hsu","year":"2023","unstructured":"Hsu, H. T. et al. Late vitreoretinal complications of regressed retinopathy of prematurity: retinal break, vitreous hemorrhage, and retinal detachment. Ophthalmol. Retina. 7, 72\u201380 (2023).","journal-title":"Ophthalmol. Retina"},{"key":"62479_CR9","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.101113998","volume":"98","author":"A Hellstrom","year":"2001","unstructured":"Hellstrom, A. et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl. Acad. Sci USA. 98, 5804\u20135808 (2001).","journal-title":"Proc Natl. Acad. Sci USA"},{"key":"62479_CR10","first-page":"182","volume":"40","author":"H Ozaki","year":"1999","unstructured":"Ozaki, H. et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest. Ophthalmol. Vis. Sci. 40, 182\u2013189 (1999).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"62479_CR11","first-page":"526","volume":"118","author":"J Chen","year":"2008","unstructured":"Chen, J., Connor, K. M., Aderman, C. M. & Smith, L. E. Erythropoietin deficiency decreases vascular stability in mice. J. Clin. Invest. 118, 526\u2013533 (2008).","journal-title":"J. Clin. Invest."},{"key":"62479_CR12","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett, M. E. & Penn, J. S. Mechanisms and management of retinopathy of prematurity. N Engl. J. Med. 367, 2515\u20132526 (2012).","journal-title":"N Engl. J. Med."},{"key":"62479_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","volume":"116","author":"T Sato","year":"2009","unstructured":"Sato, T., Kusaka, S., Shimojo, H. & Fujikado, T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116, 1599\u20131603 (2009).","journal-title":"Ophthalmology"},{"key":"62479_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ajo.2010.08.037","volume":"151","author":"T Sato","year":"2011","unstructured":"Sato, T., Shima, C. & Kusaka, S. Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity. Am. J. Ophthalmol. 151, 353\u2013357e1 (2011).","journal-title":"Am. J. Ophthalmol."},{"key":"62479_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bbrc.2017.05.067","volume":"488","author":"K Sugioka","year":"2017","unstructured":"Sugioka, K., Saito, A., Kusaka, S., Kuniyoshi, K. & Shimomura, Y. Identification of vitreous proteins in retinopathy of prematurity. Biochem. Biophys. Res. Commun. 488, 483\u2013488 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"62479_CR16","doi-asserted-by":"crossref","unstructured":"Lundgren, P. et al. Proteomic profile in retinopathy of prematurity: a secondary analysis of the mega donna mega randomized clinical trial. JAMA Ophthalmol. e255594 (2026).","DOI":"10.1001\/jamaophthalmol.2025.5594"},{"key":"62479_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/path.2858","volume":"224","author":"V Sivakumar","year":"2011","unstructured":"Sivakumar, V., Foulds, W. S., Luu, C. D., Ling, E. A. & Kaur, C. Retinal ganglion cell death is induced by microglia derived pro-inflammatory cytokines in the hypoxic neonatal retina. J. Pathol. 224, 245\u2013260 (2011).","journal-title":"J. Pathol."},{"key":"62479_CR18","doi-asserted-by":"publisher","first-page":"e3381","DOI":"10.1371\/journal.pone.0003381","volume":"3","author":"DS Dace","year":"2008","unstructured":"Dace, D. S., Khan, A. A., Kelly, J. & Apte, R. S. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS ONE. 3, e3381 (2008).","journal-title":"PLoS One"},{"key":"62479_CR19","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1378\/chest.117.4.1162","volume":"117","author":"SM Opal","year":"2000","unstructured":"Opal, S. M. & DePalo, V. A. Anti-inflammatory cytokines. Chest 117, 1162\u20131172 (2000).","journal-title":"Chest"},{"key":"62479_CR20","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1167\/iovs.08-3256","volume":"50","author":"G Byfield","year":"2009","unstructured":"Byfield, G., Budd, S. & Hartnett, M. E. The role of supplemental oxygen and JAK\/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest. Ophthalmol. Vis. Sci. 50, 3360\u20133365 (2009).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"62479_CR21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ajpath.2011.11.031","volume":"180","author":"H Wang","year":"2012","unstructured":"Wang, H. et al. VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. Am. J. Pathol. 180, 1243\u20131253 (2012).","journal-title":"Am. J. Pathol."},{"key":"62479_CR22","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","volume":"41","author":"C Iwahashi","year":"2021","unstructured":"Iwahashi, C. et al. Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity. Retina 41, 2261\u20132268 (2021).","journal-title":"Retina"},{"key":"62479_CR23","doi-asserted-by":"publisher","first-page":"785292","DOI":"10.3389\/fped.2022.785292","volume":"10","author":"C Kondo","year":"2022","unstructured":"Kondo, C. et al. Characteristics of eyes developing retinal detachment after anti-vascular endothelial growth factor therapy for retinopathy of prematurity. Front. Pediatr. 10, 785292 (2022).","journal-title":"Front. Pediatr."},{"key":"62479_CR24","doi-asserted-by":"crossref","unstructured":"Chiang, M. F. et al. International classification of retinopathy of prematurity, third edition. Ophthalmology 28, 51\u201368 (2021).","DOI":"10.1016\/j.ophtha.2021.05.031"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62479-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62479-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62479-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:02:39Z","timestamp":1792069359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62479-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62479"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62479-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9744316\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32417"}}